FRCPath Haem Part 1 MCQ-Oncology 172

A 65yr-old man with relapsed/refractory multiple myeloma has received lines of therapy previously. Now started on Elranatamab. What is its mechanism of action?

• Proteasome inhibition
• Anti-CD38 monoclonal antibody
• BCL-2 inhibition
• Bispecific antibody binding BCMA and CD3

See All Options

Want to read more?

Subscribe to hematomorph.com to keep reading this exclusive post.

Subscribe Now